Archives

Enhanced (NYSE: ENHA) to Build AI-Native Technology Within its Live Enhanced Consumer Platform with Rezolve Ai (NASDAQ: RZLV) in Multi-Million Dollar Strategic Partnership

B Rezolve Ai technology to power Live Enhanced platform to accelerate scaling and efficiency Rezolve Ai to serve as official AI technology partner of The… Login to continue reading Login…

Read MoreEnhanced (NYSE: ENHA) to Build AI-Native Technology Within its Live Enhanced Consumer Platform with Rezolve Ai (NASDAQ: RZLV) in Multi-Million Dollar Strategic Partnership

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

B      — Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13) to bring a first-in-class therapeutic to patients in atopic dermatitis… Login to continue reading Login…

Read MoreTriveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market

B Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena… Login to continue reading Login…

Read MoreElanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market